JAB-21822 for advanced pancreatic or other solid tumors with KRAS G12C
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific change in the KRAS gene called G12C (confirmed by a special lab test).
- You must have pancreatic cancer or another solid tumor (except lung or colorectal cancer) that is advanced and cannot be removed by surgery, or that has spread.
- If you have pancreatic cancer, you must have already tried gemcitabine or FOLFIRINOX (or similar chemo) and it stopped working or you couldn't tolerate it. For other cancers, you must have tried at least one standard treatment.
- You cannot have taken any other KRAS G12C inhibitor drug before (e.g., sotorasib or adagrasib).
- You must not have a history of certain serious lung diseases or uncontrolled fluid buildup in the chest or belly.
- Your heart's electrical activity (EKG) must be within normal range, and you must not be taking certain heart medicines that could cause dangerous rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial compares a new targeted pill (DN022150) with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12D gene change. It aims to see if the new drug works better at shrinking tumors and improving survival.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests an experimental pill (JAB-23E73) for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink or slow the growth of these cancers.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hear when a new KRAS P.G12C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.